Royce & Associates LP Takes Position in Fluidigm Co. (FLDM)

Share on StockTwits

Royce & Associates LP bought a new position in Fluidigm Co. (NASDAQ:FLDM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 148,400 shares of the medical research company’s stock, valued at approximately $1,279,000. Royce & Associates LP owned approximately 0.38% of Fluidigm as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. Primecap Management Co. CA increased its holdings in Fluidigm by 1.1% in the third quarter. Primecap Management Co. CA now owns 5,856,043 shares of the medical research company’s stock worth $43,862,000 after purchasing an additional 64,000 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in Fluidigm by 0.5% in the third quarter. Neuberger Berman Group LLC now owns 4,535,180 shares of the medical research company’s stock worth $33,971,000 after purchasing an additional 24,186 shares in the last quarter. BlackRock Inc. increased its holdings in Fluidigm by 9.1% in the fourth quarter. BlackRock Inc. now owns 2,139,878 shares of the medical research company’s stock worth $18,445,000 after purchasing an additional 178,429 shares in the last quarter. Vanguard Group Inc. increased its holdings in Fluidigm by 9.5% in the third quarter. Vanguard Group Inc. now owns 1,410,526 shares of the medical research company’s stock worth $10,565,000 after purchasing an additional 121,815 shares in the last quarter. Finally, Vanguard Group Inc increased its holdings in Fluidigm by 9.5% in the third quarter. Vanguard Group Inc now owns 1,410,526 shares of the medical research company’s stock worth $10,565,000 after purchasing an additional 121,815 shares in the last quarter.

FLDM has been the subject of a number of research reports. UBS Group initiated coverage on Fluidigm in a research note on Friday. They issued a “neutral” rating for the company. Zacks Investment Research cut Fluidigm from a “hold” rating to a “strong sell” rating in a research note on Friday, February 8th. Piper Jaffray Companies raised their price objective on Fluidigm from $10.00 to $14.00 and gave the company an “overweight” rating in a research note on Wednesday. BidaskClub raised Fluidigm from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. Finally, BTIG Research initiated coverage on Fluidigm in a research note on Wednesday. They issued a “buy” rating and a $15.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $14.00.

Shares of Fluidigm stock opened at $13.81 on Friday. The company has a quick ratio of 1.45, a current ratio of 1.85 and a debt-to-equity ratio of 7.56. Fluidigm Co. has a 52 week low of $4.65 and a 52 week high of $14.50. The company has a market capitalization of $551.27 million, a price-to-earnings ratio of -17.26 and a beta of 2.40.

Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings data on Thursday, February 7th. The medical research company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.07. Fluidigm had a negative return on equity of 90.07% and a negative net margin of 52.24%. The firm had revenue of $32.33 million during the quarter, compared to analysts’ expectations of $30.55 million. As a group, research analysts predict that Fluidigm Co. will post -0.71 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://weekherald.com/2019/03/15/royce-associates-lp-takes-position-in-fluidigm-co-fldm.html.

Fluidigm Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Further Reading: SEC Filing

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.